Cargando…

Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients

OBJECTIVE: This study aimed to investigate the pathological effects of long-term postoperative endocrine medication on the endometrium in breast cancer patients. METHODS: Data of 99 patients with primary breast cancer who underwent hysteroscopy and obtained endometrial biopsy from 1 June 2018 to 31...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yue, Li, Yu-He, Geng, Yu-Ning, Liu, Aihui, Gao, Feng-Yun, Ji, Chen, Liu, Yang, Wang, Ming, Li, Xing-Ming, Wang, Yan, Wu, Yu-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460202/
https://www.ncbi.nlm.nih.gov/pubmed/37637707
http://dx.doi.org/10.2147/IJGM.S417965
_version_ 1785097591498735616
author He, Yue
Li, Yu-He
Geng, Yu-Ning
Liu, Aihui
Gao, Feng-Yun
Ji, Chen
Liu, Yang
Wang, Ming
Li, Xing-Ming
Wang, Yan
Wu, Yu-Mei
author_facet He, Yue
Li, Yu-He
Geng, Yu-Ning
Liu, Aihui
Gao, Feng-Yun
Ji, Chen
Liu, Yang
Wang, Ming
Li, Xing-Ming
Wang, Yan
Wu, Yu-Mei
author_sort He, Yue
collection PubMed
description OBJECTIVE: This study aimed to investigate the pathological effects of long-term postoperative endocrine medication on the endometrium in breast cancer patients. METHODS: Data of 99 patients with primary breast cancer who underwent hysteroscopy and obtained endometrial biopsy from 1 June 2018 to 31 December 2021 at the Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital were prospectively collected. RESULTS: Hysteroscopy was performed followed by endometrial histopathological examination in 99 breast cancer patients, including 44 taking tamoxifen (TAM), 26 taking other endocrine drugs, and 29 not taking endocrine drugs. The endometrial thickness in the TAM group was significantly higher than that in the other endocrine drug groups and the group not taking endocrine drugs (p=0.017). The receiver operating characteristic curves for the abnormal premenopausal endometrial thickening were plotted in this study; an endometrial thickness of 15.5 mm seen on ultrasound could be used as the most accurate ultrasound diagnostic threshold for the diagnosis of abnormal premenopausal endometrial hyperplasia, with an area under the curve of 0.888 (95% CI: 0.716, 1.000), a sensitivity of 100%, and a specificity of 75%, which was consistent with the results of our previous retrospective study. An endometrial thickness of ≥5 mm in postmenopausal women with breast cancer taking TAM was still used as the cut-off value for routine ultrasound diagnosis of abnormal postmenopausal endometrial hyperplasia. CONCLUSION: An ultrasound endometrial thickness (proliferative phase) of >15 mm in premenopausal patients can be used as the most accurate ultrasound diagnostic threshold for the diagnosis of abnormal endometrial hyperplasia. After menopause, an ultrasound endometrial thickness of ≥5 mm is still used as the criterion for diagnosing abnormal endometrial hyperplasia. Older patients should be monitored for signs of vaginal bleeding and fluid discharge, and hysteroscopy should be performed if necessary to ascertain the endometrial condition.
format Online
Article
Text
id pubmed-10460202
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104602022023-08-27 Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients He, Yue Li, Yu-He Geng, Yu-Ning Liu, Aihui Gao, Feng-Yun Ji, Chen Liu, Yang Wang, Ming Li, Xing-Ming Wang, Yan Wu, Yu-Mei Int J Gen Med Original Research OBJECTIVE: This study aimed to investigate the pathological effects of long-term postoperative endocrine medication on the endometrium in breast cancer patients. METHODS: Data of 99 patients with primary breast cancer who underwent hysteroscopy and obtained endometrial biopsy from 1 June 2018 to 31 December 2021 at the Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital were prospectively collected. RESULTS: Hysteroscopy was performed followed by endometrial histopathological examination in 99 breast cancer patients, including 44 taking tamoxifen (TAM), 26 taking other endocrine drugs, and 29 not taking endocrine drugs. The endometrial thickness in the TAM group was significantly higher than that in the other endocrine drug groups and the group not taking endocrine drugs (p=0.017). The receiver operating characteristic curves for the abnormal premenopausal endometrial thickening were plotted in this study; an endometrial thickness of 15.5 mm seen on ultrasound could be used as the most accurate ultrasound diagnostic threshold for the diagnosis of abnormal premenopausal endometrial hyperplasia, with an area under the curve of 0.888 (95% CI: 0.716, 1.000), a sensitivity of 100%, and a specificity of 75%, which was consistent with the results of our previous retrospective study. An endometrial thickness of ≥5 mm in postmenopausal women with breast cancer taking TAM was still used as the cut-off value for routine ultrasound diagnosis of abnormal postmenopausal endometrial hyperplasia. CONCLUSION: An ultrasound endometrial thickness (proliferative phase) of >15 mm in premenopausal patients can be used as the most accurate ultrasound diagnostic threshold for the diagnosis of abnormal endometrial hyperplasia. After menopause, an ultrasound endometrial thickness of ≥5 mm is still used as the criterion for diagnosing abnormal endometrial hyperplasia. Older patients should be monitored for signs of vaginal bleeding and fluid discharge, and hysteroscopy should be performed if necessary to ascertain the endometrial condition. Dove 2023-08-22 /pmc/articles/PMC10460202/ /pubmed/37637707 http://dx.doi.org/10.2147/IJGM.S417965 Text en © 2023 He et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
He, Yue
Li, Yu-He
Geng, Yu-Ning
Liu, Aihui
Gao, Feng-Yun
Ji, Chen
Liu, Yang
Wang, Ming
Li, Xing-Ming
Wang, Yan
Wu, Yu-Mei
Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title_full Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title_fullStr Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title_full_unstemmed Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title_short Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients
title_sort prospective exploratory study of the effects of postoperative endocrine medication on the endometrium in breast cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460202/
https://www.ncbi.nlm.nih.gov/pubmed/37637707
http://dx.doi.org/10.2147/IJGM.S417965
work_keys_str_mv AT heyue prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT liyuhe prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT gengyuning prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT liuaihui prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT gaofengyun prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT jichen prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT liuyang prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT wangming prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT lixingming prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT wangyan prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients
AT wuyumei prospectiveexploratorystudyoftheeffectsofpostoperativeendocrinemedicationontheendometriuminbreastcancerpatients